Health and Healthcare

SynCardia Prepares For IPO

Medical interface
Thinkstock
Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given in the filing but the offering is valued up to $40 million. The company intends to file on the NASDAQ Global Market under the symbol TAHT.

The sole underwriter for the offering is Roth Capital Partners.

This is a medical technology company focused on developing, manufacturing and commercializing the SynCardia temporary Total Artificial Heart (TAH-t), an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.

The SynCardia TAH-t is the only total artificial heart that is commercially available in the U.S., Europe and Canada for use as a bridge to heart transplantation. As a total artificial heart, the SynCardia TAH-t replaces the functionality of both the left and right ventricles of the heart as well as all four heart valves. In combination with an external driver that delivers precisely calibrated pulses of air, the SynCardia TAH-t provides blood flow of up to 9.5 liters per minute through each ventricle, lowering central venous pressure and promoting the recovery of other vital organs.

The company requires each medical center to be trained and certified in the implantation of the SynCardia TAH-t and appropriate patient aftercare before it will sell its device to the center. SynCardia refer to centers that have successfully completed these certification programs as “SynCardia Certified Centers.” At the end of June, 2015, over 1,470 SynCardia TAH-ts (including predecessors) had been implanted across 120 medical centers globally.

In the filing SynCardia detailed its use of the proceeds to pay down its indebtedness as well as funding for clinical trials, building sales and marketing capabilities, and for working capital and general corporate purposes. Separately the company said that it expects that the net proceeds from this offering and the existing cash and cash equivalents, together with potential cash receipts from the sale of its products, will be sufficient to fund operations through at least the next 12 months.

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.